Posted by Michael Wonder on 27 Apr 2023
Seres Therapeutics and Nestlé Health Science announce FDA approval of Vowst (fecal microbiota spores, live-brpk) for prevention of recurrence of C. difficile infection in adults following antibacterial treatment for recurrent CDI
26 April 2023 - First and only FDA approved orally administered microbiota-based therapeutic, validating Seres’ microbiome platform.
Seres Therapeutics and Nestlé Health Science today announced the US FDA approval of Vowst (fecal microbiota spores, live-brpk), formerly called SER-109, an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection (CDI) in adults following antibacterial treatment for recurrent CDI.
